brentuximab vedotin (adcetris) Report issue

Biologics mAb ADC Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seattle Genetics in the US.   Wikipedia

Drug Pricing (per unit)

Australia

$3609.0215

United States

$5535.3900 - $7586.1641
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

adcetris | brentuximab | brentuximab vedotin | bretuximab vedotin | cac10-1006 | cac10-vcmmae | sgn-35

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue